158,091 Shares in Intuitive Surgical, Inc. (NASDAQ:ISRG) Bought by Seilern Investment Management Ltd

Seilern Investment Management Ltd acquired a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 158,091 shares of the medical equipment provider's stock, valued at approximately $82,517,000. Intuitive Surgical makes up about 4.7% of Seilern Investment Management Ltd's investment portfolio, making the stock its 14th biggest position.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. State Street Corp boosted its position in shares of Intuitive Surgical by 1.4% during the third quarter. State Street Corp now owns 15,050,121 shares of the medical equipment provider's stock valued at $7,393,673,000 after buying an additional 210,363 shares during the last quarter. FMR LLC boosted its holdings in Intuitive Surgical by 8.3% during the 3rd quarter. FMR LLC now owns 10,971,085 shares of the medical equipment provider's stock worth $5,389,765,000 after acquiring an additional 838,793 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Intuitive Surgical by 1.9% in the 3rd quarter. Geode Capital Management LLC now owns 7,512,925 shares of the medical equipment provider's stock worth $3,677,194,000 after acquiring an additional 143,440 shares in the last quarter. Fisher Asset Management LLC raised its holdings in shares of Intuitive Surgical by 1.8% in the third quarter. Fisher Asset Management LLC now owns 4,782,381 shares of the medical equipment provider's stock valued at $2,349,441,000 after purchasing an additional 86,208 shares during the last quarter. Finally, Baillie Gifford & Co. lifted its position in shares of Intuitive Surgical by 0.6% during the third quarter. Baillie Gifford & Co. now owns 3,848,547 shares of the medical equipment provider's stock valued at $1,890,676,000 after purchasing an additional 24,183 shares in the last quarter. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Stock Performance

Shares of ISRG stock traded up $8.56 on Monday, hitting $592.64. 2,630,118 shares of the company's stock traded hands, compared to its average volume of 1,158,623. The company's fifty day simple moving average is $540.66 and its 200 day simple moving average is $499.64. Intuitive Surgical, Inc. has a one year low of $362.14 and a one year high of $597.68. The stock has a market capitalization of $211.09 billion, a price-to-earnings ratio of 95.28, a P/E/G ratio of 4.66 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.24 by $0.32. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. The firm had revenue of $2.04 billion for the quarter, compared to analysts' expectations of $2.01 billion. As a group, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Intuitive Surgical news, insider Jamie Samath sold 22,903 shares of the firm's stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $525.00, for a total transaction of $12,024,075.00. Following the completion of the transaction, the insider now owns 8,757 shares of the company's stock, valued at approximately $4,597,425. This trade represents a 72.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Gary S. Guthart sold 18,151 shares of the company's stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $511.63, for a total value of $9,286,596.13. Following the completion of the sale, the chief executive officer now owns 24,219 shares in the company, valued at $12,391,166.97. The trade was a 42.84 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 48,190 shares of company stock worth $25,012,927. 0.80% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Evercore ISI reaffirmed a "cautious" rating on shares of Intuitive Surgical in a report on Friday, October 18th. Erste Group Bank raised Intuitive Surgical from a "hold" rating to a "buy" rating in a research report on Tuesday, November 19th. Wells Fargo & Company boosted their price target on shares of Intuitive Surgical from $549.00 to $630.00 and gave the stock an "overweight" rating in a report on Wednesday, December 11th. Leerink Partners lifted their price objective on shares of Intuitive Surgical from $489.00 to $502.00 in a research report on Thursday, October 17th. Finally, Morgan Stanley raised shares of Intuitive Surgical from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $522.00 to $650.00 in a research report on Monday, December 2nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $554.17.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.